A

Asahi Kasei

Diversified chemicals, materials, healthcare conglomerate

Manufacturing Associate - Downstream

Contract
$25 - $30/hr
Junior, Mid
Associate's
Fremont, CA, USA
In Person
Manufacturing & Production OperationsMachine & Process Operation

About the job

Requirements
  • An associate degree with 1–2 years of relevant experience, or an equivalent combination of experience or a relevant advanced degree, preferably in a biopharmaceutical manufacturing role.
  • Experience with process monitoring software and equipment software, including UNICORN and Pi Historian.
  • The ability to identify more efficient methods to address issues and gaps.
  • The ability to work independently and on cross-functional teams.
  • The ability to prioritize assignments and manage multiple projects simultaneously.
Responsibilities
  • Execute, with oversight from qualified staff, complex unit operations including chromatography, tangential flow filtration, depth filtration, virus filtration, and buffer preparation in current good manufacturing practice manufacturing suites.
  • Maintain required training in compliance with site requirements.
  • Support equipment troubleshooting, pilot-scale material generation, non-current good manufacturing practice toxicology material generation, and current good manufacturing practice downstream manufacturing activities.
  • Author, review, and approve technical documents such as technology transfer protocols and reports, production batch records, training materials, manufacturing standard operating procedures, and regulatory filing documents according to project needs.
  • Document work according to current good manufacturing practice and current good documentation practice.
  • Adhere to established regulations and site current good manufacturing practice requirements.
  • Maintain cleanroom standards, practices, and housekeeping according to standard operating procedures.
  • Identify minor equipment issues and immediately notify leads or managers of issues and discrepancies.
  • Contribute to quality activities such as investigations and area walk-throughs, and support authoring deviations, corrective and preventive actions, and change controls.
  • Perform other assigned duties and work flexible shifts.
Desired Qualifications
  • Working knowledge of current good manufacturing practice compliance as it pertains to procedures, processes, and manufacturing.
  • Working knowledge of industry-standard purification processes, including affinity, ion exchange chromatography, size-exclusion chromatography, viral inactivation and filtration, depth filtration, tangential flow filtration, and ultrafiltration/diafiltration, as well as related equipment such as GE AKTA systems and disposable components.

About the company

Asahi Kasei operates in chemicals, advanced materials, health care, and housing. Its products include polymers, rubber, battery separators, and filtration media for automotive and electronics; dialysis equipment, biomaterials, and diagnostic reagents for medical use; and insulation and interior materials for homes. The company differentiates itself through long‑term, collaborative R&D across multiple growth areas and by linking material performance with biomedical and housing applications, while pursuing environmental and social governance initiatives. Its goal is to maintain steady industrial revenue while expanding growth in sustainability, health, and advanced technologies globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1922

Get referred to Asahi Kasei

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Aicuris closed in 2026, targeting positive operating income after amortization from FY2028.
  • September 15, 2026 VANTIJ SU-VFC Benchtop deepens gene-therapy manufacturing automation.
  • Acetolyte licensing in China and Europe expands battery-material revenue without heavy capex.

What critics are saying

  • Canada separator plant slipped to 2029 or later after North American EV demand weakened.
  • Mizushima petrochemical exits through 2030 destroy ¥34.6 billion revenue and force customer requalification.
  • China patent litigation against Songxuan and Changlong keeps Duranol licensing and enforcement costs alive.

What makes Asahi Kasei unique

  • Asahi Kasei pairs Hipore battery separators with coatings, giving EV customers integrated performance.
  • Aicuris acquisition broadens Asahi Kasei from materials into specialty anti-infective pharmaceuticals.
  • Its diversified portfolio spans chemicals, housing, and healthcare, smoothing cyclical industrial swings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Asahi Kasei
Sep 20th, 2026
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy | Asahi Kasei

Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris), a German-based biopharmaceutical company. This closing ...

Calcalist Tech
Sep 17th, 2026
Israeli medtech FIZE Medical raises $20M for AI-guided ICU fluid management platform

Israeli medtech company FIZE Medical has raised $20 million in a Series B round co-led by Asahi Kasei Medical and Rapha Capital Management. The funding will advance development of FIZE Optima, an AI-driven platform designed to predict fluid-related risks in intensive care patients. FIZE has developed the FIZE kUO system, which monitors kidney function and manages fluid balance in critically ill patients through real-time digital urine output monitoring. The company is expanding its strategic partnership with Asahi Kasei Medical, which will now distribute FIZE's products in both Japan and Europe. Approximately 50% of intensive care patients develop acute kidney injury during hospitalisation, with a mortality rate exceeding 20%. FIZE's technology aims to enable early detection and intervention. The company, which began operations in 2019, employs 40 people.

Plant Prefab
Sep 16th, 2026
Plant Prefab Announces $30 Million Financing and the Opening of a Second Factory

Custom homes, sensibly built.

Associated Press
Sep 15th, 2026
Asahi Kasei launches VANTIJ SU-VFC Benchtop to streamline gene therapy production

Asahi Kasei Bioprocess has launched the VANTIJ® SU-VFC Benchtop, a small-format automated system for virus filtration in gene therapy manufacturing. The system was unveiled at Bioprocess International East 2026 in Boston. The benchtop platform is the first in Asahi Kasei's VANTIJ® family designed for laboratory-scale and process development applications. It features tool-free installation, guided setup, and recipe-driven software to streamline workflows using Planova™ virus-removal filters. The system addresses operational challenges in gene therapy production, including long timelines, regulatory requirements, and operator training needs. It offers batch reporting and supports consistent execution of filtration processes. The launch reflects Asahi Kasei's focus on supporting cell and gene therapies, a rapidly growing segment within biopharmaceuticals and a strategic priority for the company's healthcare sector.

Yahoo Finance
Aug 20th, 2026
Asahi Kasei develops lithium pre-doping tech to boost battery energy density 10% at lower cost

Asahi Kasei has developed a lithium pre-doping technology for high-voltage lithium-ion batteries with silicon-based anodes, addressing capacity loss issues that typically occur during initial charge-discharge cycles. The technology enables lithium carbonate to serve as an additional lithium source at lower voltages by using special electrolyte additives. Internal tests with an NMC cell containing an anode of 90% graphite and 10% SiO showed a 10% increase in energy density. The solution uses low-cost lithium carbonate and can be applied to existing battery manufacturing lines without significant modifications. The development targets growing demand from electric vehicles and humanoid robots, which require higher energy densities. Asahi Kasei will conduct proof-of-concept evaluations with customers worldwide to explore practical applications.